Search Results
Your search for ASCO,ASCO matches 21206 pages
Showing 13151 - 13200Metastatic Urothelial Carcinoma: A Model Malignancy for Immune Checkpoint Blockade
Platinum-based combination chemotherapy became a mainstay of first-line treatment for metastatic urothelial cancer in the 1980s. With combination platinum-based regimens, 40% to 50% of patients achieve an objective response to treatment. However, aside from approximately 5% to 10% of patients who...
The Ongoing Challenges of Lung Cancer Screening
Lung cancer persistently remains the leading cause of cancer death among men and women in the United States. Only about 15% of lung cancers are diagnosed at the localized stage, when clinical intervention could markedly improve patient outcomes. For decades, lung cancer specialists and advocacy...
FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site-Agnostic Indication
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...
Neratinib in Combination With Ado‑trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Puma Biotechnology presented interim results from the phase Ib/II FB-10 clinical trial of the oral pan-HER family irreversible tyrosine kinase inhibitor neratinib given in combination with the antibody-drug conjugate ado-trastuzumab emtansine (also known as T-DM1, Kadcyla) at the 2017 American...
Abemaciclib Active in Metastatic Breast Cancer
In the single-arm phase II MONARCH 1 trial, the investigational cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib achieved an objective response in about 20% of heavily pretreated patients with metastatic hormone receptor–positive, HER2-negative breast cancer and a disease control rate of...
Key Gene Controlling Tumor Growth in Gliomas Pinpointed
Cedars-Sinai investigators have identified a stem cell–regulating gene that affects tumor growth in patients with brain cancer and may strongly influence survival rates of patients. The findings, published by Edwards et al in Scientific Reports,1 may move physicians closer to their goal of better...
Henry Ford Cancer Institute Appoints Spencer C. Hoover, Vice President, Executive Director
Spencer C. Hoover, a decorated U.S. Army veteran who joined Henry Ford Health System in 2015, was appointed Vice President and Executive Director of the health system’s Henry Ford Cancer Institute and cancer care services. Mr. Hoover had previously served as Vice President of Planning and Business ...
First-in-Human Clinical Trial in Children and Young Adults With Leukemia
After phase I results of Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial, published by Gardner et al in Blood,1 showed T-cell immunotherapy to be effective in sending 93% of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into complete initial...
Study Establishes Low Risk for Contralateral Breast Cancer After Diagnosis of Ductal Carcinoma in Situ
An increasing number of women with ductal carcinoma in situ are undergoing contralateral mastectomy, but the 5-year risk of cancer in the opposite breast is only about 3%, a study from Memorial Sloan Kettering Cancer Center recently found.1 Investigators hope these numbers will dissuade women from ...
Optimizing Treatment for Elderly Patients With Glioblastoma
In 2005, Stupp and colleagues published their landmark paper demonstrating in a randomized phase III trial that the addition of temozolomide to radiation increased overall survival in patients with newly diagnosed glioblastoma. Notably, patients over age 70 years were excluded from this study.1...
SU2C Names Top Researchers to $12 Million Dream Team on Colorectal Cancer
Stand Up to Cancer (SU2C) announced the formation of a “Dream Team” of top researchers to take on one of the toughest challenges in cancer research and treatment: colorectal cancer, which is expected to claim the lives of more than 50,000 Americans this year. The announcement was made at a special...
European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing After Platinum Therapy
On April 28, 2017, the European Commission approved nivolumab (Opdivo) as monotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults with disease progression on or after platinum-based therapy. Nivolumab is the first and only immuno-oncology treatment that has...
Managing Small Renal Masses: A Point-by-Point Consideration of ASCO’s Clinical Practice Guideline
As reviewed in this issue of The ASCO Post, a recent issue of the Journal of Clinical Oncology featured an ASCO Clinical Practice Guideline on the management of small renal masses reported by Finelli and colleagues.1 This comprehensive guideline is written by a group of well-regarded and...
ASCO Clinical Practice Guideline: Management of Small Renal Masses
As reported in the Journal of Clinical Oncology by Antonio Finelli, MD, of Princess Margaret Cancer Center, Toronto, and colleagues, ASCO has released a clinical practice guideline on management of small renal masses.1 The guideline was derived from an expert panel literature search for and...
Intratumoral Plasmid Interleukin-12 Boosts Response to Pembrolizumab
In patients with stage III/IV melanoma, immunologically “cold” tumors were rendered immunologically active through intratumoral injections of plasmid interleukin-12 (IL-12) combined with pembrolizumab (Keytruda).1 Describing the approach at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium,...
ASCO Provisional Clinical Opinion on Hormonal Therapy for Castration-Resistant Prostate Cancer
On April 25, ASCO issued a provisional clinical opinion on the use of second-line hormonal therapy for men with castration-resistant prostate cancer who have not yet received chemotherapy. The recommendations of this provisional clinical opinion were informed by evidence from a systematic review of ...
ASPO Honors Kurt Ribisl, PhD, With Joseph W. Cullen Memorial Award
The American Society of Preventive Oncology (ASPO) has named Kurt Ribisl, PhD, the recipient of the 2017 Joseph W. Cullen Memorial Award. ASPO presented the honor at its Annual Meeting in Seattle. In addition to receiving the award, Dr. Ribisl presented a talk on finding a solution for...
Texas Medical Center Names William F. McKeon President and CEO
The Texas Medical Center (TMC) has announced that its Board of Directors has appointed William F. McKeon as President and Chief Executive Officer (CEO) and member of the Board of Directors. Mr. McKeon previously held the position of Executive Vice President, Chief Strategy and Operating Officer....
Expert Point of View: Denise A. Galloway, PhD
Denise A. Galloway, PhD, Associate Director, Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, whose research focus is human papillomavirus (HPV), told The ASCO Post that these findings provide new data for the field. “I can’t think of a large study of oral HPV infection in...
Wendy S. Rubinstein, MD, PhD, Joins CancerLinQ LLC as Division Director, Clinical Data Management and Curation
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Dr. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ®...
Rates of Oral HPV Infection Plummet After Vaccination
Vaccination against the human papillomavirus (HPV) reduced the risk of acquiring oral HPV infections by 88%, in one of the first large studies to explore vaccination’s impact in the oropharynx. The study will be presented at the 2017 ASCO Annual Meeting, and the findings were released in advance of ...
Provision of Genetic Services to Women With Breast Cancer: We Must Do Much Better
Genetic testing for inherited cancer susceptibility is increasingly part of the care of cancer patients and their relatives. Early clinical guidelines recommended BRCA1/2 testing for women diagnosed with breast or ovarian cancer if they also have a significant family cancer history or Ashkenazi...
New Partnership Seeks to Raise Skin Cancer Awareness
The Skin Cancer Foundation recently announced a partnership with Amazon. The relationship is designed to demonstrate a shared commitment to raising awareness of the world’s most common cancer, now occurring at epidemic levels. Throughout 2017, The Skin Cancer Foundation and Amazon will work...
Leader in International Clinical Trials, Robert L. Comis, MD, FASCO, Dies at 71
Robert L. Comis, MD, FASCO, Co-Chair of the ECOG-ACRIN Cancer Research Group, succumbed to a sudden illness at his home and died on May 10, 2017, at the age of 71. A giant in national and international clinical research since 1977, Dr. Comis is known as a champion of patient access to cancer...
One in Five Cancers Diagnosed in the United States Is a Rare Cancer
About one in five cancer diagnoses in the United States is a rare cancer, according to new research from the American Cancer Society. The report, published by DeSantis et al in CA: A Cancer Journal for Clinicians, found rare cancers account for more than two in three cancers occurring in children...
FDA OCE Launches Drug Information Soundcast in Clinical Oncology (DISCO)
The FDA Drug Information Soundcast in Clinical Oncology (DISCO) is a new podcast series from the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), covering new product approvals, emerging safety information for cancer treatments, and other current topics in cancer ...
Robert Vonderheide, MD, DPhil, Named Director of Abramson Cancer Center
Robert Vonderheide, MD, DPhil, has been named the new Director of the Abramson Cancer Center (ACC) of the University of Pennsylvania. He is the Hanna Wise Professor in Cancer Research at the Perelman School of Medicine and currently serves as the ACC’s Associate Director for Translational Research ...
ASCO CEO Reflects on His First Year in Office and What Is Ahead
June 27, 2017, marks the 1-year anniversary since Clifford A. Hudis, MD, FACP, FASCO, began his tenure as Chief Executive Officer of ASCO. With the launch of the national Cancer Moonshot and the changes in the White House and Congress, it has been a year of tremendous activity drawing on all of...
The Role of Meditation in Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, present the case...
Expect Questions From Patients Who ‘Do Everything Right’ but Still Develop Cancer
A study reported in Science found that more than two-thirds of human cancers are caused by random mutations made during DNA replication.1 “The main message we would like to convey is that even for many patients who follow all of the guidelines from the advisory bodies—they don’t smoke, exercise...
Recognizing Major Role of Random Mutations in Causing Cancer Does Not Diminish Importance of Primary Prevention
Random mistakes made during DNA replication are responsible for about two-thirds of the mutations that cause human cancers, according to a study reported in Science.1 Recognizing the role of these replication errors “does not diminish the importance of primary prevention but emphasizes that not all ...
Expert Point of View: Lipika Goyal, MD
Commenting on the BILCAP study, Lipika Goyal, MD, an oncologist at Massachusetts General Hospital, Boston, said: “These results are very intriguing. There is no current standard of care for adjuvant therapy of biliary tract cancer. Our high-risk patients [ie, patients with node-positive disease,...
Adjuvant Capecitabine for Biliary Tract Cancer Yields Significant Improvement in Overall Survival
There is no standard adjuvant therapy for patients with resectable biliary tract cancer, but that may be about to change based on results of the phase III BILCAP trial.1 Adjuvant capecitabine significantly improved overall survival in the BILCAP trial, and this is the first study to show a benefit...
Daniel W. Kulp, PhD, Joins The Wistar Institute in the Vaccine Center
The Wistar Institute has announced the appointment of Daniel W. Kulp, PhD, as Associate Professor in the Vaccine Center and the Translational Tumor Immunology Program. Dr. Kulp’s research centers on how best to rationally engineer protective immune responses against emerging and harmful infectious ...
My Year of Living Wonderfully: 12 Months as ASCO President
EACH YEAR, the ASCO President chooses a theme for his or her term, which is not a trivial pursuit. Trying to think up something novel and catchy, yet not schmaltzy, is quite a challenge. However, in my year as Chair of the Scientific Program Committee for the 2010 ASCO Annual Meeting, then during...
ERRATUM: Father-Son Confusion
In the April 25 issue of The ASCO Post, we reported on a study of atezolizumab -(Tecentriq) and bevacizumab (Avastin) in metastatic kidney cancer, which had been presented at the 2017 Genitourinary Cancers Symposium. Unfortunately, we misattributed that presentation to Prof. Trevor Powles of Barts ...
New Spanish-Language Videos and Brochures From ASTRO Provide Overview of Radiation Therapy
Spanish-speaking patients with cancer have new tools to help them understand treatment options for their disease. The American Society for Radiation Oncology (ASTRO) has released a series of Spanish-language patient videos on radiation therapy for cancer, including breast, prostate, lung, brain,...
Are Oncologists Discussing Exercise With Patients?
It is well documented that physical activity benefits patients with cancer, both during and after treatment. Exercise helps patients combat both the physical and psychological impacts of cancer treatment, giving them a sense of well-being, control, stress reduction, and empowerment. However,...
First Extensive Immune Profiling of Sarcomas Shows Possible Susceptibility to Immunotherapy
Sarcomas come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers. However, a study published by Pollack et al in the journal Cancer suggests how both existing and ...
AUA 2017: Studies Highlight Shifts in Prostate Cancer Screening and Management
Active surveillance in men under 60, use of telemedicine in the management of prostate cancer, and physicians' personal prostate cancer screening preferences were all highlighted at the 2017 Annual Scientific Meeting of the American Urological Association (AUA). Active Surveillance for Low-Risk...
Alcohol Consumption May Be Associated With Higher Risk of Breast Cancer in African American Women
Alcohol intake was associated with an increased risk of breast cancer in a large study of African American women, indicating that they, like white women, may benefit from limiting their alcohol consumption, according to results of a study published by Williams et al in Cancer Epidemiology,...
AUA 2017: Phase III Study of Blue Light Cystoscopy With Optical Imaging Agent in Bladder Cancer
New phase III study results of blue light flexible cystoscopy (BLFC) with an optical imaging agent (Hexvix/Cysview) were presented by Daneshmand et al during a late-breaking plenary session at the 2017 American Urological Association (AUA) Annual Meeting (Abstract PPTLBA-02). Major Findings The...
FDA Approves Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma
Today, the U.S. Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or...
AUA 2017: Studies Examine Bladder Cancer Risk and Mortality in E-Cigarette and Traditional Smokers
Data presented at the 2017 Annual Scientific Meeting of the American Urological Association (AUA) showed harmful links between the use of e-cigarettes and bladder cancer risk, and associated the smoking of traditional cigarettes to a higher risk of mortality among patients with bladder cancer. Even ...
AUA 2017: Association of Oncotype DX Genomic Prostate Score Test With Prostate Cancer–Specific Death and Metastases in Early-Stage Disease
New results presented at the 2017 American Urological Association (AUA) Annual Meeting from a large, community-based, multicenter clinical validation study conducted at Kaiser Permanente confirmed that the Oncotype DX Genomic Prostate Score (GPS) test is a strong independent predictor of prostate...
AUA 2017: New Studies Demonstrate Impact of BRCA, DNA Repair Gene Mutations in Prostate Cancer
Data presented at the 2017 Annual Scientific Meeting of the American Urological Association (AUA) showed new findings related to the impact of certain genetic mutations on the risk and development of prostate cancer, in particular metastatic disease. Male BRCA Mutations An analysis by Mano et al...
ASCO 2017: Chance of Colon Cancer Recurrence Nearly Cut in Half in Patients Who Consume Nuts
An observational study of 826 patients with stage III colon cancer showed that those who consumed 2 ounces or more of nuts per week had a 42% lower chance of cancer recurrence and 57% lower chance of death than those who did not eat nuts. A secondary analysis revealed the benefit of nut consumption ...
ASCO 2017: HPV Vaccination May Reduce Oral HPV Infections but Is Still Underutilized
In one of the first large studies to explore the possible impact of human papillomavirus (HPV) vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was...
ASCO 2017: Gefitinib Treatment Can Delay Recurrence of Intermediate-Stage Lung Cancer
The targeted therapy gefitinib (Iressa) appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II to IIIA non–small cell lung cancer ...
ASCO 2017: Healthy Lifestyle After Colon Cancer Diagnosis Helps Extend Survival
A study of 992 patients with stage III colon cancer found that those who reported a healthy lifestyle during and following adjuvant treatment had a 42% lower chance of death and a trend for lower chance of cancer recurrence than those who had less healthy lifestyles. The study will be presented by...
